Topics
Business & Finance
-
Wednesday - August 27, 2008
New Bayer CropScience active ingredient approved in Romania:
Thiencarbazone-methyl registered in first market
Annual sales potential of more than EUR 100 million for new corn herbicide
-
Thursday - August 21, 2008
Bayer and Onyx continue clinical investigation of sorafenib:
New Trial to Evaluate Nexavar® as Adjuvant Therapy in Liver Cancer
Enrollment initiated in international phase III study
-
Tuesday - August 19, 2008
Bayer HealthCare and Regeneron Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-related Macular Degeneration
Study patients, on average, received only two additional doses following a 12-week fixed dosing period
-
Tuesday - August 12, 2008
Excellence in the Field of Communications Honored
Bayer’s Annual Report Receives International Praise
-
Thursday - August 7, 2008
Bayer Schering Pharma strengthens its oncology R&D portfolio
Bayer acquires Preclinical Anti-cancer Program from Nycomed
Company assuming full development and commercialization rights
-
Thursday - July 31, 2008
Bayer appoints Greg Babe as new CEO for U.S. Organisation
Predecessor Dr. Attila Molnar to retire
-
Wednesday - July 30, 2008
Interim report for the second quarter of 2008
Bayer continues its success
Sales up 3.6 percent to EUR 8,511 million / EBITDA before special items increases by 5.0 percent to EUR 1,896 million / EBIT before special items improves by 5.3 percent to EUR 1,248 million / Full-year guidance for CropScience raised again / Group earnings forecast confirmed
-
Wednesday - July 30, 2008
Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:
Bayer’s Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S.
Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily injection of enoxaparin while maintaining low rates of major bleeding / No evidence of safety issues attributable to rivaroxaban after long-term exposure
-
Friday - July 25, 2008
Venous Blood Clot Prevention after Elective Hip or Knee Replacement Surgery:
Bayer’s Novel Anticoagulant Rivaroxaban Recommended for Approval in the EU
Final approval from the European Commission expected within the next few months
-
Friday - July 25, 2008
Andreas Fibig named new Chairman of the Board of Management of Bayer Schering Pharma
Dr. Bernd Metzner to become new Board member of Bayer’s pharmaceuticals subsidiary / Arthur Higgins and Werner Baumann to refocus on their leadership roles in the Bayer HealthCare subgroup following the successful integration of Bayer Schering Pharma
-
Tuesday - July 8, 2008
First organ-specific diagnostic agent approved in the U.S. in more than a decade:
Primovist® approved in the U.S. for the Detection and Characterization of Liver Lesions
-
Thursday - July 3, 2008
Bayer CropScience strengthens global position in insecticides market:
Insecticide Movento® approved in United States and Canada
Launch of Movento® planned for 2008
-
Wednesday - July 2, 2008
Bayer HealthCare Completes Acquisition of Western OTC Cough and Cold Business of Topsun Science and Technology
Significantly Strengthens Consumer Care Division’s Business in High Growth Chinese OTC Market
-
Friday - June 27, 2008
Bayer at a glance:
New edition of “Names, Figures, Facts”
Service line for free booklet
-
Tuesday - June 24, 2008
Bayer concludes supply and licensing agreements for Yasmin® and YAZ® with Barr for the United States
Appeal of court decision invalidating Yasmin patent will continue / Further growth of Bayer’s Women’s Healthcare Business Unit expected
-
Monday - June 23, 2008
Bayer’s Belford Roxo site near Rio de Janeiro celebrates 50th anniversary of its founding
Bayer plans to invest EUR 100 million in Brazil
Wenning: “Brazil is our biggest market in Latin America”
-
Monday - June 23, 2008
New Bayer technology reduces power consumption and CO2 emissions by 30 percent:
Bayer receives Environmental Award from the Federation of German Industries
Energy-efficient process recycles chlorine from hydrochloric acid / Industrial application in Germany and China / Bayer Management Board member Dr. Plischke: “Increase in energy efficiency brings economic and ecological benefits”
-
Tuesday - June 3, 2008
Bayer HealthCare successfully completes acquisition of Sagmel, Inc.’s OTC Business
Bayer Consumer Care’s Presence in Eastern Europe Significantly Strengthened
-
Wednesday - May 28, 2008
Bundeskartellamt ends lawsuit against Bayer Vital
-
Wednesday - May 14, 2008
First hybrid rice variety worldwide resistant to bacterial leaf blight:
Bayer CropScience launches new high-yielding rice variety in India
Search
Publications
Stockholder's Newsletter
Annual Report 2007
Sustainable Development Report 2007
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
Events
Download Center - Selection